Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6055 in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT07905261Phase 2Not yet recruiting
- Sponsor
- Beijing Kangchuanglian Biopharmaceutical Technology Research
- Start
- Dec 2026
- Primary completion
- Dec 2029
01
Overview
A Phase 2 trial of SYS6055 in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Beijing Kangchuanglian Biopharmaceutical Technology Research. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
SYS6055
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT07905261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905261.